Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Immunogenicity of V118C in Children
NCT07300267Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Primary completion
- Oct 2028
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V118 in pneumococcal infection (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Immediate Adverse Events Following Vaccination at 30 months, Percentage of Participants With Solicited Injection-Site Adverse Events at 7 days and 4 more. Started Jan 2026; status: recruiting.
02
Drugs
V118
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07300267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300267.